10-Q: Pharma-Bio Serv Swings to Profit in Q2 2025 Amidst Strong European Growth and Improved Margins

Pharma-Bio Serv, Inc. reported a significant turnaround in its financial performance for the second quarter and first six months of fiscal year 2025, achieving net income driven by robust European market expansion and enhanced gross profit margins, despite revenue declines in other key regions.

Summary

• For the three months ended April 30, 2025, Pharma-Bio Serv reported revenues of $2,417,044, a slight increase from $2,377,617 in the same period last year.
• Gross profit for the three-month period increased significantly to $818,726 (33.9% margin) from $618,475 (26.0% margin) in the prior year, an improvement of 7.9 percentage points.
• The company swung from a loss from operations of $(313,375) in Q2 2024 to a loss of $(98,322) in Q2 2025, indicating a substantial reduction in operating losses.
• Net income for the three months ended April 30, 2025, was $95,353, a significant improvement from a net loss of $(213,817) in the comparable prior-year period.
• Basic and diluted earnings per common share for the three-month period were $0.004, up from $(0.009) in Q2 2024.
• For the six months ended April 30, 2025, total revenues increased to $4,888,377 from $4,757,804 in the prior year.
• Gross profit for the six-month period rose to $1,586,835 (32.5% margin) from $1,154,084 (24.3% margin) in the prior year, an improvement of 8.2 percentage points.
• The loss from operations for the six-month period improved to $(190,513) from $(751,675) in the prior year.
• Net income for the six months ended April 30, 2025, was $103,889, a substantial improvement from a net loss of $(484,536) in the comparable prior-year period.
• Basic and diluted earnings per common share for the six-month period were $0.005, up from $(0.021) in the prior year.
• The European market experienced a significant increase in project revenue of approximately $1.1 million for the six-month period, while Puerto Rico, US, and Brazil consulting markets saw declines of approximately $0.6 million, $0.3 million, and $0.1 million, respectively.
• Selling, general and administrative expenses decreased by $0.1 million for the six-month period ended April 30, 2025, compared to the same period last year, attributed to planned savings.
• As of April 30, 2025, cash and cash equivalents decreased to $2,093,075 from $6,767,356 at October 31, 2024, primarily due to cash dividends paid and investments in marketable securities.
• Marketable securities increased to $8,313,189 as of April 30, 2025, from $5,978,104 at October 31, 2024.
• Working capital as of April 30, 2025, was approximately $11.6 million.
• The company repurchased 29,501 shares of its common stock during the six-month period ended April 30, 2025, under its Repurchase Program, with 1,471,942 shares remaining available for future repurchases.
• A cash dividend of $0.075 per common share, totaling $1,719,918, was paid on March 20, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround, swinging from net losses to net income with significant improvements in gross profit margins and reduced operating losses. However, a notable decrease in cash and cash equivalents, coupled with the uncertainty surrounding the critical PRIDCO tax grant extension and ongoing litigation for uncollected receivables, temper the overall positive sentiment.

Positives

• The company achieved net income of $95,353 for the three months and $103,889 for the six months ended April 30, 2025, a significant turnaround from losses in the prior year periods.
• Gross profit margins improved substantially, increasing by 7.9 percentage points for the three-month period (to 33.9%) and 8.2 percentage points for the six-month period (to 32.5%), primarily due to a high-margin project in the European market.
• Loss from operations significantly narrowed for both the three-month (from $(313,375) to $(98,322)) and six-month (from $(751,675) to $(190,513)) periods.
• The European consulting market demonstrated strong growth, with revenues increasing by $0.5 million for the three-month period and $1.1 million for the six-month period compared to the prior year.
• Selling, general and administrative expenses decreased by $0.1 million for the six-month period, reflecting planned savings.
• The company maintains a healthy working capital of approximately $11.6 million as of April 30, 2025.
• The US Tax Reform Transition Tax payable was fully paid off, reducing total liabilities.

Negatives

• Cash and cash equivalents significantly decreased by $4,674,281 from October 31, 2024, to April 30, 2025, primarily due to cash dividends paid and investments in marketable securities.
• Revenues declined in the Puerto Rico, United States, and Brazil consulting markets for both the three-month and six-month periods ended April 30, 2025.
• Net cash used in operating activities increased to $(731,076) for the six months ended April 30, 2025, compared to $25,201 provided in the prior year, indicating a shift to cash consumption from operations.
• Retained earnings decreased by $1,616,029 from October 31, 2024, to April 30, 2025, largely due to the cash dividend payment.

Risks

• Uncertainty regarding the outcome of the renegotiation application for the Puerto Rico Industrial Development Company (PRIDCO) tax grant, which expired on October 31, 2024; while the company does not anticipate problems, approval is not guaranteed.
• Exposure to regional or global conflicts, including war or economic sanctions between nations, which may adversely affect future performance.
• Impact of price inflation on operations and profitability.
• Potential adverse effects from pandemics, including operational constraints imposed by customers.
• Risks associated with the Tax Reform and possible changes in tax laws in jurisdictions where the company operates.
• Challenges posed by bio-pharmaceutical industry consolidations.
• Adverse effects from trends in managing contract resources.
• Significant concentration of revenues and accounts receivable from a few customers; four customers accounted for 52.1% of revenues for the three months and 54.8% for the six months ended April 30, 2025, and 49.1% of total accounts receivable.
• Inability to collect a $6,717,431.69 judgment (including $5,246,782 principal) from Romark Global Pharma, LLC and its affiliates, as the company has been unable to identify assets for collection.

Future Outlook

The company believes its future profitability and liquidity are dependent on the effects of local and global economic conditions, including regional or global conflicts, price inflation, pandemics, changes in tax laws, worldwide life science manufacturing industry consolidations, operational constraints imposed by customers, and resource management trends. Management is actively pursuing service opportunities and adapting to industry trends to mitigate these challenges. The company anticipates sufficient working capital, operations, and cash flows to fund anticipated expenses and long-term contractual commitments for at least the next twelve months.

Management Comments

• "Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months."
• "Although we do not anticipate problems with the Grant approval, we cannot provide assurance on the outcome for our renegotiation application."

Industry Context

Pharma-Bio Serv operates in the compliance and technology transfer consulting sector, primarily serving the pharmaceutical, chemical, biotechnology, medical devices, cosmetics, and food industries. The company faces competition from local and international consulting firms. Its core business focuses on FDA and international agencies regulatory compliance. The industry is subject to global economic conditions, potential conflicts, inflation, and consolidation trends, which can impact demand for consulting services. The company's strong performance in Europe suggests a growing demand or successful market penetration in that region, potentially offsetting softer demand in its traditional Puerto Rico and US markets.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or industry benchmarks to assess the results in the context of global industry standards.

Legal Proceedings

• The company's subsidiaries (Pharma-Bio Serv PR, Inc., Pharma Serv, Inc., and Scienza Labs, Inc.) filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC, and Romark Holdings, LLC on March 15, 2023.
• A judgment was entered on November 13, 2023, ordering Romark to pay $6,717,431.69, including a principal amount of $5,246,782, plus interest.
• The company is actively pursuing assets and monies from Romark to collect the judgment but has been unable to identify assets to date.
• No further losses are expected beyond legal fees and collection costs, but a successful outcome in collecting the funds is not guaranteed.

Stakeholder Impact

• Shareholders: Positively impacted by the swing to net income and the continued cash dividend payment ($0.075 per share), as well as ongoing share repurchase program. Negatively impacted by the decrease in retained earnings due to dividends.
• Employees (Consulting Team): Compensation to the consulting team is a primary cash need, indicating continued employment and operational activity.
• Customers: Concentration of revenues from a few key customers (over 50% from four customers/global groups) indicates high reliance on these relationships, posing a risk if any relationship deteriorates.
• Creditors: The reduction in total liabilities, including the full payment of the US Tax Reform Transition Tax payable, suggests improved financial stability from a creditor's perspective.
• Regulatory Authorities: The company's compliance with SEC filing requirements and its focus on FDA and international agencies regulatory compliance services underscore its adherence to regulatory standards.

Next Steps

• Continue collection efforts for the $6.7 million judgment against Romark Global Pharma, LLC and its affiliates.
• Await status update and approval for the renegotiation of the Puerto Rico Industrial Development Company (PRIDCO) tax grant.

Key Dates

Recommendation

Keywords

Pharmaceutical consulting, Biotechnology consulting, Medical devices consulting, Compliance services, FDA regulatory compliance, Technical consulting, Puerto Rico consulting, United States consulting, Europe consulting, SEC filing, 10-Q, Financial results, Gross profit margin, Net income, Earnings per share, Tax grant, Share repurchase, Cash dividend